VivoSeq
Oncology

Ann Arbor Stage IIB Hodgkin Lymphoma

8

Pipeline Programs↗

1

Active Trials↗

5

Companies Involved↗

Ann Arbor Stage IIB Hodgkin Lymphoma is an early-stage landscape with 8 programs across 5 companies. The most active players are Pfizer, Sequus Pharmaceuticals, Gynecologic Oncology Group. 8 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

2 programs

Phase 3S

Sequus Pharmaceuticals

1 program

Phase 3G

Gynecologic Oncology Group

1 program

Phase 3A

Avyxa

1 program

Phase 3E

Eastern Cooperative Oncology Group

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

6 of 7 classified programs — the dominant modality here.

14%ALL OTHERSAntibody–drug conjugate114%

Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

1

clinical trials

Active, not recruiting1 · 100%

Clinical Trials

Trial Activity

A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Active, not recruiting·National Cancer Institute (NCI)·Phase 3·NCT02166463·600 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)